PRA Health Sciences, Inc. ( PRAH Quick Quote PRAH - Free Report) rallies 4.3% on Nov 5 after reporting strong earnings results.
The company reported third-quarter 2020 EPS of $1.30, beating the Zacks Consensus Estimate by 15%. The bottom line, however, fell from the prior-year quarter tally by 1.5%.
The company recorded revenues of $796.3 million in the quarter under review, up 2% year over year and 3.8% at cc. The figure surpassed the Zacks Consensus Estimate by 3.7%.
Results in Detail Segmental Analysis
Net new business at the Clinical Research segment came in at $737.9 million, indicating growth of 10.2% from the prior-year quarter. Through the segment, the company receives contracts to provide clinical research services, with payments based on fixed-fee or fee-for-service arrangements.
Revenues at the Clinical Research segment amounted to $732.1 million, up 1.8% year over year while revenues at the Data Solutions segment amounted to $64.2 million, up 4.1% year over year.
Direct costs totaled $412.1 million in the quarter, up 5.9% from the prior-year quarter. Per management, the increase was primarily driven by a rise in labor-related costs at the Clinical Research and higher data costs in Data Solutions segments.
Gross profit came in at $384.2 million, down 1.8%. Gross margin came in at 48.3%, highlighting a contraction of 188 basis points (bps).
Adjusted operating profit in the quarter grossed $268.8 million, down 9.1% from the year-ago quarter. Adjusted operating margin in the quarter was 33.8%, down 414 bps.
The company exited the third quarter of 2020 with cash and cash equivalents of $336.2 million, up from $168.2 million at the end of the second quarter.
Cumulative net cash provided by operating activities totaled $267.1 million compared with that of $65.9 million in the year-ago period.
For 2020, PRA Health raised revenue projection to $3.12-$3.15 billion. The Zacks Consensus Estimate for the same stands at $3.10 billion.
Adjusted EPS for 2020 is expected within $4.61 and $4.71 (compared to previous range of $4.35-$4.55). The Zacks Consensus Estimate for the same stands at $4.43.
PRA Health ended the third quarter on a strong note. Solid performance by both the Clinical Research and Data Solutions segments is a major positive. PRA Health continues to gain from large pharmaceutical companies and is also well-poised on Contract Research Organization market prospects.
On the flip side, direct costs shot up in the quarter under review. Contraction in both margins is a concern as well.
Zacks Rank and Key Picks
PRA Health currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced their quarterly results are
Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) , Align Technology, Inc. ( ALGN Quick Quote ALGN - Free Report) and AngioDynamics, Inc. ( ANGO Quick Quote ANGO - Free Report) , each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>